Supernus Pharmaceuticals (SUPN)
(Delayed Data from NSDQ)
$35.51 USD
+0.41 (1.15%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $35.50 -0.01 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
C Value A Growth D Momentum A VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SUPN 35.51 +0.41(1.15%)
Will SUPN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SUPN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SUPN
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
SUPN: What are Zacks experts saying now?
Zacks Private Portfolio Services
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?
Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say
Other News for SUPN
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics | SUPN Stock News
Supernus completes acquisition of Sage Therapeutics
Biogen rises as Alzheimer’s therapy drives Q2 beat
Supernus (SUPN) Receives Upgrade and Increased Price Target
Supernus (SUPN) Receives Upgrade from Cantor Fitzgerald